SURPASS-1 studied tirzepatide against placebo in adults whose type 2 diabetes was inadequately controlled by diet and exercise alone. Its publication record includes a correction that must accompany final review. Primary trial Linked correction record
Study snapshot
The 40-week double-blind phase 3 trial randomized 478 participants across three tirzepatide groups and placebo. HbA1c change was the primary endpoint. The indexed report describes greater glycemic and weight improvements with tirzepatide and gastrointestinal adverse events. It separately reports discontinuation of study drug and premature discontinuation of the study. Eli Lilly funded the trial. Primary trial
Our appraisal: stopping treatment is not necessarily stopping observation
A participant can stop assigned treatment while still contributing follow-up measurements. Treating every drug discontinuation as a lost participant can misdescribe the evidence. Conversely, continued enrollment does not necessarily mean every endpoint was measured.
A useful participant-flow table therefore distinguishes randomized, exposed, still on treatment, still followed, and included in each analysis. The report's definitions and missing-data methods determine how these categories relate.
The correction notice is a separate verification task. Its existence does not imply retraction or misconduct, but it means an unchecked earlier version should not be treated as final. This draft deliberately avoids a detailed numerical efficacy table until the correction's scope and updated report are reconciled.
Frequently asked questions
Was this the semaglutide comparison trial?
No. SURPASS-1 used placebo; SURPASS-2 is a different study.
Did this evaluate a monotherapy setting?
Yes, in the population described by the trial.
Is stopping study drug the same as leaving all follow-up?
Not necessarily.
Does a correction mean the paper was retracted?
No. Those are different publication statuses.
Has this draft fully resolved the correction?
No. Its scope must be inspected and reconciled before release.
Can this historical trial establish every current treatment claim?
No. Population, comparator, outcomes, and later evidence still matter.
What was reviewed here?
The indexed primary abstract and publication relationships; complete correction and full-report review remain explicit requirements.